- Home
- GNTA vs XLO Comparison
GNTA vs XLO Comparison
Compare GNTA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | XLO |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 39.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | XLO |
|---|---|---|
| Price | $0.88 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 53.4K | ★ 441.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.46 |
| 52 Week High | $10.00 | $1.18 |
Technical Indicators
Market Signals| Indicator | GNTA | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 34.34 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.70 | $0.74 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 17.75 | 31.21 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.